Geneva, Sept. 25 -- International Clinical Trials Registry received information related to the study (NCT07820098) titled 'Topical Delgocitinib for Facial Vitiligo' on Sept. 9.

Study Type: Interventional

Study Design: Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Lone Skov

Condition: Vitiligo

Intervention: Drug: Delgocitinib cream

Recruitment Status: Not recruiting

Phase: Phase 2

Date of First Enrollment: April 8, 2026

Target Sample Size: 12

Countries of Recruitment: Denmark

To know more, visit https://clinicaltrials.gov/study/NCT07820098

Published by HT Digital Content Services with permission from Health Daily Digest....